Interestingly, a more recent longitudinal study from our group identified serum VEGF as 1 out of 12 immune mediators to be increased in a group of 13 European chronic HCV patients who developed de novo HCC within 18 months of HCV therapy compared to matching controls. Here, VEGFA is linked to hepatocellular carcinoma.